Activates LXR-β and suppresses SREBP-1 to enhance symptoms in metabolic syndromes; potent inhibitory effect on in vitro bone resorption; anti-inflammatory, anti-oxidant activity; inhibition of cancer cell invasion through blocking the PKCδ/MAPK/AP-1 (Wang et al., 2015; Hoang et al., 2015). Here, PRKCD is linked to metabolic syndrome.